Celldex Therapeutics is a biopharmaceutical company focused on developing therapeutic antibodies for severe inflammatory, allergic, and autoimmune diseases. The company's lead candidate, barzolvolimab (CDX-0159), is a monoclonal antibody that binds the KIT receptor to inhibit mast cell activity, currently in Phase 3 trials for chronic spontaneous urticaria and Phase 2 trials for prurigo nodularis and atopic dermatitis. Celldex is also developing CDX-622, a bispecific antibody targeting TSLP and SCF pathways, which is in Phase 1 trials for asthma and other inflammatory conditions. The company operates in the dermatology and immunology sectors, addressing unmet medical needs in mast cell-mediated diseases.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage celldex.com
Sector Healthcare IR page ir.celldex.com
Tags
mast cell biology, monoclonal antibodies, bispecific antibodies, urticaria, atopic dermatitis, prurigo nodularis, asthma, kit receptor, tslp, scf, barzolvolimab, CDX-0159, CDX-622
Press page —

Metrics

Valuation  
Market cap $ 2.545B
Market cap (USD) $ 2.545B
P/E -7.52
PEG —
P/BV 3.92
P/S —
P/OCF -10.10
P/FCF -9.80
Dividend yield —
Turnover / mcap —
Returns  
ROE -40.6%
ROI -51.8%
ROIC -43.2%
Profit margin -16,748.0%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 33
Quality score -88.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000 FY 1999 FY 1998
Revenue 1.545M 7.02M 6.883M 2.357M 4.651M 7.418M 3.573M 9.538M 12.743M 6.786M 5.48M 3.586M 4.111M 11.202M 9.265M 46.793M 15.18M 7.456M 5.103M 4.931M 3.088M 6.859M 4.633M 6.705M 3.346M — 1.484M 2.15M
Net profit -258.757M -157.863M -141.429M -112.325M -70.511M -59.78M -50.878M -151.184M -93.031M -128.53M -127.197M -118.08M -81.55M -59.123M -44.799M -2.533M -36.525M -47.501M -21.639M -20.374M -18.097M -13.204M -12.67M -13.829M -22.753M -21.975M -11.309M -51.8M
Free cash flow -213.659M -159.697M -109.109M -105.56M -62.158M -41.956M -47.146M -76.048M -101.719M -115.787M -103.763M -103.466M -71.888M -50.085M -36.167M -32.472M -30.397M 16.975M -24.279M 17.676M -8.193M -13.999M -11.95M — -21.431M -4.609M -9.228M -9.147M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000 FY 1999 FY 1998
Share price 27.16 25.27 39.66 44.57 38.64 17.52 2.23 0.2 2.84 3.54 15.68 18.25 24.21 6.71 2.5 3.76 4.69 6.11 — — — — — — — — — —
Price performance 12m 0.07 -0.36 -0.11 0.15 1.21 6.86 10.27 -0.93 -0.2 -0.77 -0.14 -0.25 2.61 1.68 -0.34 -0.2 -0.23 — — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — — — 3.66M 3.48M 3.04M 4.03M 2.54M 3.81M 2.34M
Cash and deposits (USD) 42.5M 40.3M 24.3M 11.2M 43.8M 39.1M 29.4M 34.8M 28.4M 28.9M
Intangible assets (USD) 81.5M 67.6M 48.7M 48.7M 30.7M 27.2M 27.2M 27.2M 27.2M 27.2M
Right-of-use assets (USD) — — — 3.47M 3.45M 2.97M 4M 2.58M 3.9M 2.44M
Cash flow detail
Operating cash flow (USD) -113M -99.9M -75.2M -46.4M -40.4M -60.9M -104M -107M -158M -211M
Purchases of property, plant and equipment (USD) -2.75M -1.79M -813,000 -731,000 -1.55M -1.25M -1.83M -1.82M -1.92M -2.71M
Change in payables (cash effect) (USD) -4.97M -8.74M -13.1M -321,000 1.64M 3.65M 3.12M 9.38M 11.6M 11M
Income taxes paid (cash effect) (USD) — — — — — — — 0.00 0.00 0.00
Share-based compensation (USD) 15.3M 12.3M 8.08M 4.55M 3.92M 8.95M 15.6M 23.9M 34.2M 36.2M
Free cash flow (OCF - PPE - intangibles) (USD) -116M -102M -76M -47.1M -42M -62.2M -106M -109M -160M -214M
Income detail
Research and development expense (USD) 103M 96.2M 66.4M 42.7M 42.5M 53.3M 82.3M 118M 164M 245M
↳ 5y CAGR +25.9% +15.2% -0.3% -16.4% -15.7% -12.3% -3.1% +12.2% +30.8% +41.9%
Total comprehensive income (USD) -128M -93M -151M -50.8M -59.8M -71.2M -113M -139M -158M -258M
Comprehensive income to owners (USD) -128M -93M -151M -50.8M -59.8M -71.2M -113M -139M -158M -258M
Reported Mar 14, 2017 Mar 7, 2018 Mar 7, 2019 Mar 26, 2020 Mar 29, 2021 Feb 28, 2022 Feb 28, 2023 Feb 25, 2026 Feb 25, 2026 Feb 25, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Nov 5, 2026

PDF Version

  • Best-in-disease results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 studies showed rapid, profound, sustained efficacy supporting barzolvolimab’s potential to be a transformational therapy in CSU

  • BLA submission for barzolvolimab in CSU anticipated in 2027

  • Phase 3 barzolvolimab cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) actively enrolling

  • Excellent progress across all earlier stage pipeline programs

HAMPTON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2026 and provided a corporate update.

“Barzolvolimab has significant potential to address enormous populations of high unmet need and shift the treatment paradigm goal from symptom improvement to complete symptom resolution, which for patients means no itch, no hives, no swelling,” said Anthony Marucci, Co-founder, President and Chief Executive Officer at Celldex. “This quarter we reported best-in-disease results from our two Phase 3 studies in CSU, demonstrating barzolvolimab’s unparalleled ability to deliver complete response to patients—including even in patient populations suffering with severe disease or severe angioedema or with omalizumab refractory disease. We are moving quickly to bring this much needed medicine to patients and physicians. We are also making excellent progress advancing our ongoing Phase 3 study in symptomatic dermographism and cold urticaria and look forward to updating on these programs in 2027.

“Building on our leading science clinically validating the therapeutic potential of KIT inhibition in immune and inflammatory diseases, we will continue to chart the future of mast cell medicine, expanding barzolvolimab and CDX-622 development across a diverse spectrum of immune and inflammatory diseases and adding to our growing mast cell targeted pipeline to bring our science to additional patient populations that could benefit.”

Recent Program Highlights

Barzolvolimab- KIT Inhibitor Program

Barzolvolimab is a first-in-class humanized monoclonal antibody with a novel mechanism of action that targets mast cells by binding with high specificity to a unique part of the KIT receptor and potently inhibiting its activity. The KIT receptor is abundantly expressed by mast cells and critical for their function and survival. Mast cells are drivers of inflammatory responses such as hypersensitivity and allergic reactions and, in certain inflammatory diseases, such as chronic urticarias, mast cell activation plays a central role in the onset and progression of the disease.

Chronic Urticarias

  • In September 2026, the Company reported best-in-disease topline results from the Phase 3 EMBARQ-CSU1 and -CSU2 studies of barzolvolimab in patients with CSU whose symptoms are inadequately controlled by H1-antihistamines. The primary and all key secondary endpoints across both studies and both dose groups were met. Results showed rapid, profound, and sustained efficacy, including unprecedented complete response rates, supporting barzolvolimab’s potential to be a transformational therapy in CSU. Efficacy was sustained or deepened from Weeks 12 to 24, and barzolvolimab was well-tolerated with a favorable safety profile through 24 weeks, consistent with prior studies. Statistically significant and clinically meaningful benefit was also seen in antihistamine refractory patients with severe disease or severe angioedema, as well as in patients with CSU refractory to omalizumab. Treatment in both EMBARQ-CSU trials will continue to 52 weeks, and the Company anticipates a BLA submission in 2027.

Data from the Phase 3 studies reported to date are consistent with results from the completed Phase 2 CSU study. In Phase 2, the primary endpoint was met at Week 12 and patients on study continued to receive barzolvolimab for a total of 52 weeks of treatment. Sustained and deepening disease efficacy and a well-tolerated long term safety profile were demonstrated over the 52-week treatment period. In addition, at 76 weeks, 7 months after the completion of dosing with barzolvolimab, over 40% of patients (150mg Q4W) continued to experience profound, sustained complete response and up to 64% of patients treated with barzolvolimab who had angioedema at baseline remained angioedema-free, supporting barzolvolimab’s disease modifying potential.

  • Enrollment is ongoing in Celldex’s global Phase 3 study in cold urticaria (ColdU) and symptomatic dermographism (SD)—EMBARQ-ColdU and -SD. Barzolvolimab is the first drug in development to demonstrate clinical benefit in patients with ColdU and SD in a large, randomized, placebo-controlled study. In the Phase 2 study, all primary and secondary endpoints were met with high statistical significance at 12 weeks and sustained through the end of the 20-week treatment period. Patients with disease recurrence during the main study follow-up period qualified for an Open Label Extension (OLE). Barzolvolimab retreatment achieved similar profound efficacy to first exposure in patients with ColdU and SD.

Additional Indications Celldex has clinically validated the therapeutic potential of the novel KIT inhibition mechanism of action with barzolvolimab and continues to grow the Company’s pipeline across a diverse spectrum of immune and inflammatory diseases where mast cells are a critical driver.

  • Additional indications for barzolvolimab will be announced by year end.

  • Enrollment is complete in the Phase 2 study in atopic dermatitis (AD). This randomized, double-blind, placebo-controlled, parallel group study is evaluating the efficacy and safety profile of barzolvolimab in patients with moderate to severe AD. Topline data from this study are expected to be presented in late 2026.

  • Topline data from the Phase 2 study in prurigo nodularis (PN) were presented in July 2026 and suggested that mast cells may not be the key pathogenic driver in PN. Based on these results, Celldex is discontinuing the Phase 2 PN study. Barzolvolimab was well-tolerated and demonstrated a favorable safety profile consistent with prior studies.

Novel Bispecific Antibody (BsAb) Platform

Celldex continues to drive groundbreaking science and is the first company to directly demonstrate that neutralizing soluble stem cell factor (SCF) can selectively inhibit KIT signaling in mast cells—a historically challenging target. Celldex's approach provides a clinically-validated anchor mechanism that enables the development of diverse BsAb candidates where a dual mechanism approach may overcome the heterogeneity inherent in the pathophysiology of many inflammatory disorders, expanding into new indications and broader patient populations that can benefit from our medicines. CDX-622 is the first candidate from this leading science, with additional BsAbs soon to follow.

  • CDX-622 (SCF & TSLP) targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin (TSLP) and depleting mast cells via stem cell factor (SCF) starvation. Combined neutralization of soluble SCF and TSLP with CDX-622 is expected to simultaneously reduce tissue mast cells and inhibit Type 2 inflammatory responses, allowing for a complementary dual mechanism approach that may overcome the heterogeneity inherent in the pathophysiology of many inflammatory disorders. Results from the Phase 1 trial in healthy volunteers demonstrated rapid, profound, dose-dependent, and durable reductions in serum tryptase, without impacting other KIT-dependent functions. CDX-622 also exhibited monoclonal antibody-like pharmacokinetics, with extended half-life and good exposure with subcutaneous administration, consistent with good bioavailability. CDX-622 was well-tolerated in all study parts and at all dose levels.

  • An open-label, single-dose Phase 1 proof of mechanism (POM) study is ongoing to assess the safety, pharmacodynamics, and pharmacokinetics of CDX-622 in adults with mild to moderate asthma. The Company plans to advance expansion into additional indications with CDX-622, including allergic rhinitis and food allergy.

Third Quarter 2026 Financial Highlights and 2026 Guidance

Cash Position: Cash, cash equivalents and marketable securities as of September 30, 2026 were $650.3 million compared to $717.6 million as of June 30, 2026. The decrease was primarily driven by third quarter cash used in operating activities of $65.0 million. At September 30, 2026, Celldex had 78.5 million shares outstanding.

Revenues: No material revenue was recognized in the third quarter of 2026 or the nine months ended September 30, 2026, compared to $0.0 million and $1.4 million for the comparable periods in 2025, respectively. The decrease in revenue was primarily due to a decrease in services performed under our manufacturing and research and development agreements with Rockefeller University.

R&D Expenses: Research and development (R&D) expenses were $67.4 million in the third quarter of 2026 and $208.0 million for the nine months ended September 30, 2026, compared to $62.9 million and $169.7 million for the comparable periods in 2025. The increase in R&D expenses was primarily due to an increase in barzolvolimab clinical trial and contract manufacturing expense as well as an increase in employee headcount to support the development of barzolvolimab.

G&A Expenses: General and administrative (G&A) expenses were $14.8 million in the third quarter of 2026 and $39.4 million for the nine months ended September 30, 2026, compared to $10.7 million and $31.9 million for the comparable periods in 2025. The increase in G&A expenses was primarily due to an increase in barzolvolimab commercial planning expenses and an increase in employee headcount to support the commercialization of barzolvolimab.

Net Loss: Net loss was $75.6 million, or ($0.96) per share, for the third quarter of 2026, and $227.7 million, or ($3.06) per share, for the nine months ended September 30, 2026, compared to a net loss of $67.0 million, or ($1.01) per share, for the third quarter of 2025, and $177.4 million, or ($2.67) per share, for the nine months ended September 30, 2025.

Financial Guidance: Celldex believes that the cash, cash equivalents and marketable securities at September 30, 2026 are sufficient to meet estimated working capital requirements and fund current planned operations through 2028.

About Celldex Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders. Visit www.celldex.com.

Forward Looking Statement This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of Company drug candidates, including barzolvolimab (also referred to as CDX-0159) and CDX-622, in current or future indications; the uncertainties inherent in clinical testing and accruing patients for clinical trials; our limited experience in bringing programs through Phase 3 clinical trials; our current expectations regarding the submission of a Biologics License Application (“BLA”) to the FDA in 2027; our ability to manage and successfully complete multiple clinical trials and the research and development efforts for our multiple products at varying stages of development; the availability, cost, delivery and quality of clinical materials produced by our own manufacturing facility or supplied by contract manufacturers, who may be our sole source of supply; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to continue to develop; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; our ability to continue to obtain capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; and other factors listed under "Risk Factors" in our annual report on Form 10-K and quarterly reports on Form 10-Q.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contacts Sarah Cavanaugh Senior Vice President, Corporate Affairs & Administration (508) 864-8337 [email protected]

Elizabeth Higgins Executive Director, Investor Relations & Corporate Communications (857) 404-2088 [email protected]

| |

| CELLDEX THERAPEUTICS, INC. |

| (In thousands, except per share amounts) |

| | | | | | | | | | |

| | | | Three Months | | Nine Months |

| Consolidated Statements of Operations Data | | Ended September 30, | | Ended September 30, |

| | | | | 2026 | | | | 2025 | | | | 2026 | | | | 2025 | |

| | | | (Unaudited) | | (Unaudited) |

| Revenues: | | | | | | | | |

| Product development and licensing agreements | | $ | - | | | $ | - | | | $ | 7 | | | $ | 57 | |

| Contracts and grants | | | - | | | | - | | | | 30 | | | | 1,367 | |

| | | | | | | | | | |

| Total revenues | | | - | | | | - | | | | 37 | | | | 1,424 | |

| | | | | | | | | | |

| Operating expenses: | | | | | | | | |

| Research and development | | | 67,407 | | | | 62,931 | | | | 207,950 | | | | 169,741 | |

| General and administrative | | | 14,844 | | | | 10,686 | | | | 39,396 | | | | 31,897 | |

| | | | | | | | | | |

| Total operating expenses | | | 82,251 | | | | 73,617 | | | | 247,346 | | | | 201,638 | |

| | | | | | | | | | |

| Operating loss | | | (82,251 | ) | | | (73,617 | ) | | | (247,309 | ) | | | (200,214 | ) |

| | | | | | | | | | |

| Investment and other income, net | | | 6,694 | | | | 6,573 | | | | 19,564 | | | | 22,774 | |

| | | | | | | | | | |

| Net loss | | $ | (75,557 | ) | | $ | (67,044 | ) | | $ | (227,745 | ) | | $ | (177,440 | ) |

| | | | | | | | | | |

| Basic and diluted net loss per common share | | $ | (0.96 | ) | | $ | (1.01 | ) | | $ | (3.06 | ) | | $ | (2.67 | ) |

| | | | | | | | | | |

| Shares used in calculating basic and diluted net loss per share | | | 78,531 | | | | 66,420 | | | | 74,356 | | | | 66,399 | |

| | | | | | | | | | |

| Condensed Consolidated Balance Sheet Data | | September 30 | | December 31 |

| | | | | 2026 | | | | 2025 | |

| | | | (Unaudited) | | |

| Assets | | | | |

| Cash, cash equivalents and marketable securities | | $ | 650,319 | | | $ | 518,573 | |

| Other current assets | | | 13,417 | | | | 16,091 | |

| Property and equipment, net | | | 10,997 | | | | 5,334 | |

| Intangible and other assets, net | | | 46,798 | | | | 42,985 | |

| | Total assets | | $ | 721,531 | | | $ | 582,983 | |

| | | | | | |

| Liabilities and stockholders' equity | | | | |

| Current liabilities | | $ | 60,517 | | | $ | 50,991 | |

| Long-term liabilities | | | 11,545 | | | | 4,827 | |

| Stockholders' equity | | | 649,469 | | | | 527,165 | |

| | Total liabilities and stockholders' equity | | $ | 721,531 | | | $ | 582,983 | |

| | | | | | |

Primary Logo

Source: Celldex Therapeutics, Inc.

Investor & Media Inquiries

Sarah Cavanaugh Senior Vice President Corporate Affairs and Administration [email protected]

Investor & Media Inquiries

Sarah Cavanaugh Senior Vice President Corporate Affairs and Administration [email protected]

Celldex to Present at Upcoming Investor Conferences Bull 0 Bear 0 Routine

Nov 4, 2026

PDF Version

HAMPTON, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming investor conferences:

  • The Guggenheim 3rd Annual Healthcare Innovation Conference on November 9, 2026 at 9:00am ET.

  • The 9th Annual Evercore Healthcare Conference on December 1, 2026 at 10:50am ET.

The webcasts of the Guggenheim and Evercore presentations will be available on the “Events and Presentations” page of the “Investors” section of the Celldex Website. Replays will be available for 90 days following the event.

About Celldex Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders. Visit www.celldex.com.

Company Contacts Sarah Cavanaugh Senior Vice President, Corporate Affairs & Administration (508) 864-8337 [email protected]

Elizabeth Higgins Executive Director, Investor Relations & Corporate Communications (857) 404-2088 [email protected]

Primary Logo

Investor & Media Inquiries

Sarah Cavanaugh Senior Vice President Corporate Affairs and Administration [email protected]

Investor & Media Inquiries

Sarah Cavanaugh Senior Vice President Corporate Affairs and Administration [email protected]

Sep 22, 2026

  • Best-in-disease results showed rapid, profound, sustained efficacy, supporting barzolvolimab’s potential to be a transformational therapy in CSU

  • EMBARQ-CSU1 and -CSU2 met primary and all key secondary endpoints at 12 weeks across both studies and both dose groups

  • Clinically meaningful and statistically significant benefit demonstrated in omalizumab refractory CSU and patients with severe disease or severe angioedema

  • Efficacy sustained or deepened from weeks 12 to 24

  • Well tolerated with a favorable safety profile through 24 weeks; consistent with prior studies

  • Treatment will continue in both trials to 52 weeks; BLA submission anticipated in 2027

  • Company to host webcast today at 8:00 am ET

HAMPTON, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported positive topline results from the Company’s Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials evaluating two doses of barzolvolimab in patients with chronic spontaneous urticaria (CSU) whose symptoms are inadequately controlled by H1-antihistamines. The EMBARQ-CSU1 and EMBARQ-CSU2 studies are the largest program conducted in antihistamine refractory CSU, including patients with advanced therapy experienced/refractory CSU. Both Phase 3 trials met the primary endpoint of mean change from baseline in weekly urticaria activity score (UAS7) at Week 12, and all key secondary endpoints, demonstrating clinically meaningful and statistically significant improvements in disease activity. Barzolvolimab was well-tolerated through the 24 week placebo controlled treatment period with a favorable safety profile consistent with prior Phase 2 experience. The EMBARQ-CSU trials are ongoing, with treatment continuing through 52 weeks. The Company intends to present the EMBARQ-CSU data at an upcoming medical meeting and plans to submit a Biologics License Application (BLA) to the FDA in 2027.

“We are proud of the results shared today and believe that barzolvolimab has the potential to address the enormous unmet need in CSU,” said Diane Young, MD, Senior Vice President and Chief Medical Officer of Celldex. “Barzolvolimab continued to show unprecedented complete response rates across the overall studies and demonstrated strong differentiation in patient populations underserved by existing therapies, including those with severe disease or angioedema, and those whose disease is refractory to omalizumab. We believe that barzolvolimab can be a transformational therapy for people living with CSU and thank the CSU community, trial participants, and investigators around the world for their support of the EMBARQ-CSU trials and the entire barzolvolimab clinical program.”

"The results from our two Phase 3 EMBARQ-CSU trials showed efficacy that is best-in-disease in CSU,” said Anthony Marucci, Co-Founder, President, and Chief Executive Officer at Celldex. “We believe barzolvolimab is well-positioned to address large CSU populations of high unmet need—as a first-line therapy for patients with severe CSU or angioedema, and as the second-line advanced therapy of choice. We look forward to continuing to grow our leadership in mast cell biology as we advance to our next stage of development—establishing a commercial-stage organization committed to delivering barzolvolimab to patients and physicians in need as quickly as possible.”

Summary of Key Findings

Data cutoff: September 9, 2026

The Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 studies demonstrated rapid, profound, sustained efficacy consistent with Phase 2 and unparalleled in CSU. Efficacy was sustained or deepened from weeks 12 to 24 across primary and all key secondary endpoints

| Primary Endpoint: Mean Change from Baseline in UAS7 at Week 12: |

| | EMBARQ-CSU1 | EMBARQ-CSU2 |

| | Baseline UAS7 | LS Mean Change (SE) at Week 12 | Baseline UAS7 | LS Mean Change (SE) at Week 12 |

| Placebo | 30.9 | -10.7 (0.65) | 29.3 | -11.4 (0.64) |

| 150 mg Q4W | 30.6 | -20.2 (0.64) (p<.00001) | 29.7 | -20.2 (0.63) (p<.00001) |

| 300 mg Q8W | 30.3 | -20.5 (0.65) (p<.00001) | 29.6 | -19.7 (0.64) (p<.00001) |

P-values are for LS Mean treatment difference versus placebo.

  • The primary endpoint showed clinically meaningful and highly statistically significant improvement.

Key Secondary Endpoints: All key secondary endpoints in both EMBARQ-CSU trials were met at Week 12 with high statistical significance and were clinically meaningful.

Given the importance of Complete Response (complete absence of itch and hives) to patients and physicians, and barzolvolimab’s unique ability to drive sustained Complete Response, the Company is presenting UAS7=0 data observed at both 12 and 24 weeks.

| Proportion of Patients with Complete Response (UAS7=0) at Weeks 12 and 24 |

| | EMBARQ-CSU1 | EMBARQ-CSU2 |

| | 12 Weeks |

| Placebo | 9.3% | 12.6% |

| 150 mg Q4W | 42.4% (p<.00001) | 45.7% (p<.00001) |

| 300 mg Q8W | 42.1% (p<.00001) | 44.0% (p<.00001) |

| | 24 Weeks |

| Placebo | 15.4% | 17.6% |

| 150 mg Q4W | 49.0% (p<.00001) | 54.0% (p<.00001) |

| 300 mg Q8W | 45.1% (p<.00001) | 48.4% (p<.00001) |

P-values are based on adjusted odds ratio of logistic regression models.

  • Significantly more patients achieved Complete Response (UAS7=0) with both barzolvolimab doses vs. placebo at Weeks 12 and 24.

| Proportion of Patients with Complete Response (UAS7=0) at Week 12 in Omalizumab-Refractory CSU |

| | EMBARQ-CSU1 | EMBARQ-CSU2 |

| Placebo | 9.3% | 15.1% |

| 150 mg Q4W | 55.3% (p<.00001) | 41.7% (p=.0089) |

| 300 mg Q8W | 44.3% (p=.00017) | 46.4% (p=.0036) |

P-values are based on adjusted odds ratio of logistic regression models.

  • A higher proportion of patients achieved Complete Response (UAS7=0) vs placebo at Week 12 in the sub-population of patients with CSU refractory to omalizumab.

| Proportion of Patients with AAS7=0 at Week 12 in Patients with Baseline AAS7>0 |

| | EMBARQ-CSU1 | EMBARQ-CSU2 |

| Placebo | 33.8% | 33.7% |

| 150 mg Q4W | 62.7% (p<.00001) | 74.3% (p<.00001) |

| 300 mg Q8W | 66.3% (p<.00001) | 66.2% (p<.00001) |

P-values are based on adjusted odds ratio of logistic regression models.

  • A statistically higher proportion of patients achieved complete resolution of angioedema (AAS7=0) at Week 12 vs. placebo in patients with baseline AAS7>0.

Barzolvolimab was well-tolerated and demonstrated a favorable safety profile consistent with prior experience through the end of the placebo controlled period at Week 24.

The Phase 3 EMBARQ-CSU1 and CSU2 studies are ongoing. A BLA submission is planned for 2027.

Prompts

Celldex Therapeutics, Inc. (ticker CLDX), listed in United States.

Company History

Date Change Detail
Nov 6, 2009 Acquired Acquired Curagen Corp (CIK 1030653). Its filings from before the deal are on its own company page, not shown here.
Nov 5, 2008 Renamed AVANT IMMUNOTHERAPEUTICS INC → CELLDEX THERAPEUTICS, INC.

ETFs Holding Celldex Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
SURI 0.89% 21,629 $ 606.477K Nov 17, 2026
TMSL 0.19% 139,948 $ 5.207M Jun 30, 2026
FFSM 0.15% 58,481 $ 2.226M Jul 31, 2026
FSEV 0.14% 256 $ 9,525.76 Jun 30, 2026
RESM 0.09% 89 $ 3,311.69 Jun 30, 2026
FSEG 0.05% 73 $ 2,716.33 Jun 30, 2026
DFAS 0.04% 456,816 $ 13.033M Nov 12, 2026
MSSM 0.02% 3,898 $ 154.478K Aug 31, 2026
FESM 0.02% 28,403 $ 1.057M Jun 30, 2026
DFAC 0.01% 234,868 $ 6.701M Nov 12, 2026
DCOR 0.01% 83,515 $ 2.383M Nov 12, 2026
DFAU 0.00% 17,411 $ 496.736K Nov 12, 2026
DFSU 0.00% 2,758 $ 78.686K Nov 12, 2026
DFUS 0.00% 22,082 $ 629.999K Nov 12, 2026
DXUV 0.00% 4,133 $ 117.914K Nov 12, 2026
AVUS 0.00% 636 $ 18.183K Nov 16, 2026
AVSC 0.00% 2,009 $ 57.437K Nov 16, 2026